The GOLPH2 antibody targets GOLPH2 (Golgi phosphoprotein 2), also known as Golgi membrane protein GP73 or GOLM1. This transmembrane protein is primarily localized in the Golgi apparatus and plays a role in secretory pathways. Initially identified in the context of liver function, GOLPH2 is expressed in normal epithelial cells but shows elevated levels in pathological conditions, particularly hepatocellular carcinoma (HCC) and prostate cancer. Its upregulation is associated with viral infections (e.g., hepatitis B/C) and tumor progression, making it a potential biomarker for early cancer detection and monitoring.
GOLPH2 antibodies are widely used in research and diagnostics to detect protein expression via immunohistochemistry (IHC), Western blot, or ELISA. In clinical studies, GOLPH2 overexpression correlates with poor prognosis, suggesting its utility in risk stratification. However, its biological mechanisms remain partially unclear, with proposed roles in vesicle trafficking, immune modulation, or cellular stress responses. Commercially available antibodies vary in specificity, often validated for cross-reactivity across species (human, mouse, rat). Recent interest in GOLPH2 has expanded to neurodegenerative diseases, where Golgi dysfunction is implicated. Despite its promise, standardization of detection methods and clearer validation in diverse cohorts are needed to enhance its diagnostic reliability.